Hui Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hui Zhang has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
Zhengkai Lu
State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Science and Technology, Tongji University, China (Z.L., J.T.).
10 shared publications- Juan Tang
State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Science and Technology, Tongji University, Shanghai, China
8 shared publications Jufeng Meng
School of Life Science and Technology, ShanghaiTech University, Shanghai, China
8 shared publications- Bin Zhou
CAS CEMCS-CUHK Joint Laboratory, New Cornerstone Science Laboratory, Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
7 shared publications Chao-Po Lin
7 shared publicationsShan Kou
School of Life Science and Technology, ShanghaiTech University, Shanghai, China
7 shared publications
Latest Publications
- 5 May 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (18) , 1385-1401
P16 + Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes
BACKGROUND: Ischemic heart disease remains a leading cause of mortality worldwide, with adverse remodeling after myocardial infarction driven by inflammation and cardiomyocyte loss. Although cytotoxic lymphocytes exacerbate myocardial injury and P16 marks cellular senescence in diseased hearts, the cell type–specific functions of P16 + populations remain unclear. METHODS: Using p16-CreER;R26-tdT reporter mice, we mapped P16 + cell heterogeneity after myocardial infarction. Senolytic effects were assessed with combined dasatinib and quercetin treatment. Transcriptomic profiling (bulk and single-cell RNA sequencing) of sorted P16 + cells identified secreted factors, validated through in silico predictions and quantitative polymerase chain reaction. Intercellular communication was analyzed using CellChat. Functional relevance was tested through CCL8 (cytokine [C-C motif] ligand 8) neutralization, Ccl8 deletion in P16 + cells, lymphocyte depletion, and intersectional genetic ablation of P16 + fibroblasts or macrophages using dual-recombinase systems ( p16-DreER;Pdgfra-CreER;R26-lr-tdT-DTR and p16-DreER;Cx3cr1-CreER;R26-lr-tdT-DTR ). RESULTS: P16 was induced in fibroblasts, macrophages, coronary endothelial cells, and cardiomyocytes after myocardial infarction. Dasatinib and quercetin treatment selectively eliminated P16 + macrophages and fibroblasts, improving cardiac function. Transcriptomic analysis identified P16 + fibroblasts and macrophages as the main sources of CCL8. CCL8 blockade reduced infiltration of cytotoxic lymphocytes (CD8 + T cells and natural killer cells), decreased cardiomyocyte apoptosis, and enhanced repair. Genetic deletion of Ccl8 in P16 + cells reproduced these benefits. It is important to note that ablation of P16 + fibroblasts, but not macrophages, diminished fibrosis and improved function, and depletion of CD8 + T cell attenuated adverse remodeling. CONCLUSIONS: P16 + cells orchestrate maladaptive remodeling after myocardial infarction through CCL8-dependent recruitment of cytotoxic lymphocytes, particularly CD8 + T cells, which drive cardiomyocyte apoptosis. Targeting P16 + fibroblasts or blocking CCL8 offers a promising therapeutic approach for ischemic heart disease.
- 5 May 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (18) , 1385-1401
P16 + Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes
BACKGROUND: Ischemic heart disease remains a leading cause of mortality worldwide, with adverse remodeling after myocardial infarction driven by inflammation and cardiomyocyte loss. Although cytotoxic lymphocytes exacerbate myocardial injury and P16 marks cellular senescence in diseased hearts, the cell type–specific functions of P16 + populations remain unclear. METHODS: Using p16-CreER;R26-tdT reporter mice, we mapped P16 + cell heterogeneity after myocardial infarction. Senolytic effects were assessed with combined dasatinib and quercetin treatment. Transcriptomic profiling (bulk and single-cell RNA sequencing) of sorted P16 + cells identified secreted factors, validated through in silico predictions and quantitative polymerase chain reaction. Intercellular communication was analyzed using CellChat. Functional relevance was tested through CCL8 (cytokine [C-C motif] ligand 8) neutralization, Ccl8 deletion in P16 + cells, lymphocyte depletion, and intersectional genetic ablation of P16 + fibroblasts or macrophages using dual-recombinase systems ( p16-DreER;Pdgfra-CreER;R26-lr-tdT-DTR and p16-DreER;Cx3cr1-CreER;R26-lr-tdT-DTR ). RESULTS: P16 was induced in fibroblasts, macrophages, coronary endothelial cells, and cardiomyocytes after myocardial infarction. Dasatinib and quercetin treatment selectively eliminated P16 + macrophages and fibroblasts, improving cardiac function. Transcriptomic analysis identified P16 + fibroblasts and macrophages as the main sources of CCL8. CCL8 blockade reduced infiltration of cytotoxic lymphocytes (CD8 + T cells and natural killer cells), decreased cardiomyocyte apoptosis, and enhanced repair. Genetic deletion of Ccl8 in P16 + cells reproduced these benefits. It is important to note that ablation of P16 + fibroblasts, but not macrophages, diminished fibrosis and improved function, and depletion of CD8 + T cell attenuated adverse remodeling. CONCLUSIONS: P16 + cells orchestrate maladaptive remodeling after myocardial infarction through CCL8-dependent recruitment of cytotoxic lymphocytes, particularly CD8 + T cells, which drive cardiomyocyte apoptosis. Targeting P16 + fibroblasts or blocking CCL8 offers a promising therapeutic approach for ischemic heart disease.
- Open Access
- 25 April 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
PW1+ cells give rise to cardiac adipocytes during development and myofibroblasts following injury
Pw1, a maternally imprinted gene, is expressed in various stem cell populations, underscoring its crucial roles in tissue development, maintenance, and reg
- 25 April 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessPW1+ cells give rise to cardiac adipocytes during development and myofibroblasts following injury
Pw1, a maternally imprinted gene, is expressed in various stem cell populations, underscoring its crucial roles in tissue development, maintenance, and reg
- 4 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (9) , 623-639
Activation of Imprinted Gene PW1 Promotes Cardiac Fibrosis After Ischemic Injury
BACKGROUND: Cardiac fibrosis, characterized by excessive extracellular matrix (ECM) deposition in the myocardium, is an important target for heart disease treatments. Pw1 (paternally expressed gene 3) is an imprinted gene expressed from the paternal allele, and de novo purine biosynthesis (DNPB) is a crucial pathway for nucleotide synthesis. However, the roles of PW1 and DNPB in ECM production by cardiac fibroblasts during myocardial ischemia are not yet understood. METHODS: To induce myocardial damage, we performed left anterior descending coronary artery ligation. We generated Pw1 CreER-2A-eGFP and Pw1 2A-CreER knock-in mouse lines to evaluate the expression of the 2 Pw1 alleles in normal and injured hearts. Bisulfite sequencing was used to analyze the DNA methylation of the Pw1 imprinting control region. We identified the phosphoribosylformylglycinamidine synthase ( Pfas ) gene, encoding the DNPB enzyme PFAS, as a direct target of PW1 using chromatin immunoprecipitation sequencing and real-time quantitative polymerase chain reaction. The role of DNPB in ECM production and cardiac fibrosis after injury was examined in vitro using cultured cardiac fibroblasts and in vivo with Pfas -deficient mice. RESULTS: Our study demonstrates that myocardial infarction reduces DNA methylation at the imprinting control region of the maternally imprinted gene Pw1 , triggering a switch from monoallelic imprinting to biallelic expression of Pw1 in cardiac fibroblasts. In activated cardiac fibroblasts, increased Pw1 expression promotes purine biosynthesis and induces ECM production by transcriptionally activating the DNPB factor Pfas . We identified that DNPB is essential for ECM production in activated fibroblasts and that loss of Pfas in fibroblasts limits cardiac fibrosis and improves heart function after injury. CONCLUSIONS: This study demonstrates that Pw1 imprinting is disrupted after injury and reveals a novel role for the downstream target PFAS in ECM production and cardiac fibrogenesis. Targeting the PW1/PFAS signaling pathway presents a promising therapeutic strategy for improving cardiac repair after injury.
- 4 March 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (9) , 623-639
Activation of Imprinted Gene PW1 Promotes Cardiac Fibrosis After Ischemic Injury
BACKGROUND: Cardiac fibrosis, characterized by excessive extracellular matrix (ECM) deposition in the myocardium, is an important target for heart disease treatments. Pw1 (paternally expressed gene 3) is an imprinted gene expressed from the paternal allele, and de novo purine biosynthesis (DNPB) is a crucial pathway for nucleotide synthesis. However, the roles of PW1 and DNPB in ECM production by cardiac fibroblasts during myocardial ischemia are not yet understood. METHODS: To induce myocardial damage, we performed left anterior descending coronary artery ligation. We generated Pw1 CreER-2A-eGFP and Pw1 2A-CreER knock-in mouse lines to evaluate the expression of the 2 Pw1 alleles in normal and injured hearts. Bisulfite sequencing was used to analyze the DNA methylation of the Pw1 imprinting control region. We identified the phosphoribosylformylglycinamidine synthase ( Pfas ) gene, encoding the DNPB enzyme PFAS, as a direct target of PW1 using chromatin immunoprecipitation sequencing and real-time quantitative polymerase chain reaction. The role of DNPB in ECM production and cardiac fibrosis after injury was examined in vitro using cultured cardiac fibroblasts and in vivo with Pfas -deficient mice. RESULTS: Our study demonstrates that myocardial infarction reduces DNA methylation at the imprinting control region of the maternally imprinted gene Pw1 , triggering a switch from monoallelic imprinting to biallelic expression of Pw1 in cardiac fibroblasts. In activated cardiac fibroblasts, increased Pw1 expression promotes purine biosynthesis and induces ECM production by transcriptionally activating the DNPB factor Pfas . We identified that DNPB is essential for ECM production in activated fibroblasts and that loss of Pfas in fibroblasts limits cardiac fibrosis and improves heart function after injury. CONCLUSIONS: This study demonstrates that Pw1 imprinting is disrupted after injury and reveals a novel role for the downstream target PFAS in ECM production and cardiac fibrogenesis. Targeting the PW1/PFAS signaling pathway presents a promising therapeutic strategy for improving cardiac repair after injury.
- Open Access
- 13 August 2024
- Published by Springer Nature in Cell Discovery
- Vol. 10 (1) , 1-4
Targeting cardiac fibrosis with chimeric antigen receptor macrophages
- 13 August 2024
- Published by Springer Nature in Cell Discovery
- Vol. 10 (1) , 1-4
Open AccessTargeting cardiac fibrosis with chimeric antigen receptor macrophages
- 27 September 2023
- Published by Elsevier in Gene Expression Patterns
- Vol. 50, 119343
Expression analysis of plvap in mouse heart development, homeostasis and injury
- 27 September 2023
- Published by Elsevier in Gene Expression Patterns
- Vol. 50, 119343
Expression analysis of plvap in mouse heart development, homeostasis and injury
- Open Access
- 14 June 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-4
Identification of mesenchymal-to-epithelial transition during heart regeneration through genetic lineage tracing
The epicardium is the important outermost mesothelial/epithelial layer of the heart that serves as a signaling center for cardiac development and repair. During heart development, epicardial cells undergo a process known as epithelial-to-mesenchymal transition to form diverse mesenchymal cell lineages, such as fibroblasts, coronary vascular smooth muscle cells, and pericytes. However, it is not clear whether the reverse process, mesenchymal-to-epithelial transition (MET), takes place in the mammalian heart. In this study, we performed apical resection on neonatal hearts and used Fap-CreER;Ai9 labeling to track activated fibroblasts in the injured cardiac regions. We found that these fibroblasts underwent MET to generate epicardial cells during heart regeneration. To our knowledge, this is the first report of MET occurring in vivo during heart development and regeneration. Our findings suggest that it is feasible to directly convert fibroblasts into epicardial cells, providing a novel approach to generate epicardial cells.
- 14 June 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-4
Open AccessIdentification of mesenchymal-to-epithelial transition during heart regeneration through genetic lineage tracing
The epicardium is the important outermost mesothelial/epithelial layer of the heart that serves as a signaling center for cardiac development and repair. During heart development, epicardial cells undergo a process known as epithelial-to-mesenchymal transition to form diverse mesenchymal cell lineages, such as fibroblasts, coronary vascular smooth muscle cells, and pericytes. However, it is not clear whether the reverse process, mesenchymal-to-epithelial transition (MET), takes place in the mammalian heart. In this study, we performed apical resection on neonatal hearts and used Fap-CreER;Ai9 labeling to track activated fibroblasts in the injured cardiac regions. We found that these fibroblasts underwent MET to generate epicardial cells during heart regeneration. To our knowledge, this is the first report of MET occurring in vivo during heart development and regeneration. Our findings suggest that it is feasible to directly convert fibroblasts into epicardial cells, providing a novel approach to generate epicardial cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
A, Schematic describing the primary B-cell lymphoma PDX SCID/NSG-hu mouse model. Six-to 8-week-old male NSG or CB-17 SCID mice were implanted with human fetal bone. Approximately 4 to 6 weeks following bone implantation, one injection of 5 Ã- 106 patient tumor cells were administered directly into the human fetal bone chip as the first generation (G1). The levels of circulating human β2M in mouse serum were used to monitor tumor engraftment and growth in G1 mice. Once tumor burden was detected, the pieces of tumor with bone chip were subcutaneously transplanted into NSG mice as the second generation (G2). After G2, the consistent growths of tumor in NSG mice were acquired. Single-agent targeted therapy, drug-resistant treatment, or combination therapy, were administered in the indicated generations. B, Human β2M reflected the tumor burdens of 16 B-cell lymphomas in PDX-G1 mice. After 3-4 weeks of tumor inoculation, mouse sera were collected from the peripheral blood of tail vein, and the level of human β2M was determined by ELISA.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
A, Schematic describing the primary B-cell lymphoma PDX SCID/NSG-hu mouse model. Six-to 8-week-old male NSG or CB-17 SCID mice were implanted with human fetal bone. Approximately 4 to 6 weeks following bone implantation, one injection of 5 Ã- 106 patient tumor cells were administered directly into the human fetal bone chip as the first generation (G1). The levels of circulating human β2M in mouse serum were used to monitor tumor engraftment and growth in G1 mice. Once tumor burden was detected, the pieces of tumor with bone chip were subcutaneously transplanted into NSG mice as the second generation (G2). After G2, the consistent growths of tumor in NSG mice were acquired. Single-agent targeted therapy, drug-resistant treatment, or combination therapy, were administered in the indicated generations. B, Human β2M reflected the tumor burdens of 16 B-cell lymphomas in PDX-G1 mice. After 3-4 weeks of tumor inoculation, mouse sera were collected from the peripheral blood of tail vein, and the level of human β2M was determined by ELISA.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2. Characterization of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Representative tumor mass and histology of tumor series passages of PT1 MCL and PT2 Burkitt's lymphoma (BL). B-C, PDX tumors invaded the mouse spleen and formed splenomegaly. D, Patient abdomen PET/CT images of PT1 and PT5 showed splenomegaly (left panel). Autopsy of PT1 G3 NSG mouse and PT5 G1 SCID-hu mouse also showed splenomegaly (middle panel), and H&E staining of mouse spleens in PDXs indicated extensive lymphoma involvement (right panel).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2. Characterization of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Representative tumor mass and histology of tumor series passages of PT1 MCL and PT2 Burkitt's lymphoma (BL). B-C, PDX tumors invaded the mouse spleen and formed splenomegaly. D, Patient abdomen PET/CT images of PT1 and PT5 showed splenomegaly (left panel). Autopsy of PT1 G3 NSG mouse and PT5 G1 SCID-hu mouse also showed splenomegaly (middle panel), and H&E staining of mouse spleens in PDXs indicated extensive lymphoma involvement (right panel).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy